The Food and Drug Administration (FDA) has cleared the expanded use of bioMérieux’s Vidas Brahms PCT assay to help healthcare providers determine if they should stop antibiotic treatment in patients with sepsis and start or stop antibiotic treatment in patients with lower respiratory tract infections. Intended for use in hospital emergency settings, this is the first test to use procalcitonin (PCT) as a biomarker to help make antibiotic management decisions in patients with these conditions. FDA first cleared this assay to help clinicians better predict a patient’s risk of morbidity or mortality due to sepsis. Data supporting the test’s expanded use included clinical trial findings from published literature that compared PCT-guided therapy to standard therapy. These prospective, randomized studies showed a significant decrease in antibiotic use for patients who had received PCT-guided therapy, without significantly affecting safety.